CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors

Francesco Schettini, Irene De Santo, Carmen G Rea, Pietro De Placido, Luigi Formisano, Mario Giuliano, Grazia Arpino, Michelino De Laurentiis, Fabio Puglisi, Sabino De Placido, Lucia Del Mastro

Research output: Contribution to journalReview articlepeer-review


Cyclin-dependent kinases (CDK) 4/6 inhibitors, namely abemaciclib, palbociclib, and ribociclib, interfere with cell cycle progression, induce cell senescence and might promote cancer cell disruption by a cytotoxic T cells-mediated effect. Phase III randomized clinical trials have proven that CDK4/6 inhibitors (CDK4/6i) in combination with several endocrine agents improve treatment efficacy over endocrine agents alone for hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (MBC). Based on such results, these combinations have been approved for clinical use. Preclinical studies in cell cultures and mouse models proved that CDK4/6i are active against a broad spectrum of solid tumors other than breast cancer, including liposarcoma, rhabdomyosarcoma, non-small cell lung cancer, glioblastoma multiforme, esophageal cancer, and melanoma. The role of CDK4/6i in monotherapy in several solid tumors is currently under evaluation in phase I, II, and III trials. Nowadays, abemaciclib is the only of the three inhibitors that has received approval as single agent therapy for pretreated HR+ HER2- MBC. Here we review biological, preclinical and clinical data on the role of CDK4/6 inhibitors as single agents in advanced solid tumors.

Original languageEnglish
Pages (from-to)608
JournalFrontiers in Oncology
Publication statusPublished - 2018


Dive into the research topics of 'CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors'. Together they form a unique fingerprint.

Cite this